Truist Financial Lowers Option Care Health (NASDAQ:OPCH) Price Target to $34.00

Option Care Health (NASDAQ:OPCH - Get Free Report) had its price objective reduced by Truist Financial from $41.00 to $34.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's target price indicates a potential upside of 41.02% from the company's previous close.

OPCH has been the subject of a number of other reports. JMP Securities raised their price objective on shares of Option Care Health from $36.00 to $37.00 and gave the company a "market outperform" rating in a research report on Monday, September 30th. Jefferies Financial Group lowered shares of Option Care Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $38.00 to $26.00 in a research report on Thursday. Barrington Research cut their price objective on shares of Option Care Health from $40.00 to $32.00 and set an "outperform" rating for the company in a research report on Thursday. Finally, Bank of America lowered shares of Option Care Health from a "buy" rating to a "neutral" rating and cut their price objective for the company from $43.00 to $29.00 in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $31.60.

Option Care Health Stock Performance

NASDAQ:OPCH traded up $1.07 on Friday, reaching $24.11. 7,118,017 shares of the company's stock were exchanged, compared to its average volume of 1,473,412. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.36. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of 19.36, a P/E/G ratio of 1.79 and a beta of 1.29. Option Care Health has a 52 week low of $22.84 and a 52 week high of $34.63. The stock has a fifty day simple moving average of $30.65 and a 200-day simple moving average of $29.97.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.05. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.22 billion. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. As a group, sell-side analysts predict that Option Care Health will post 1.22 earnings per share for the current year.

Insider Activity at Option Care Health

In related news, Director Elizabeth Quadros Betten sold 47,531 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total value of $1,477,738.79. Following the sale, the director now directly owns 21,339 shares of the company's stock, valued at $663,429.51. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Elizabeth Quadros Betten sold 47,531 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total value of $1,477,738.79. Following the sale, the director now directly owns 21,339 shares of the company's stock, valued at $663,429.51. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael H. Shapiro sold 23,217 shares of Option Care Health stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now directly owns 247,317 shares in the company, valued at $7,654,461.15. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OPCH. Massachusetts Financial Services Co. MA purchased a new position in shares of Option Care Health during the second quarter worth approximately $68,003,000. Magnetar Financial LLC raised its stake in shares of Option Care Health by 124.8% during the second quarter. Magnetar Financial LLC now owns 2,481,935 shares of the company's stock worth $68,750,000 after acquiring an additional 1,377,929 shares in the last quarter. Duquesne Family Office LLC raised its stake in shares of Option Care Health by 172.8% during the second quarter. Duquesne Family Office LLC now owns 1,871,818 shares of the company's stock worth $51,849,000 after acquiring an additional 1,185,613 shares in the last quarter. Hood River Capital Management LLC grew its holdings in shares of Option Care Health by 77.2% in the second quarter. Hood River Capital Management LLC now owns 1,729,029 shares of the company's stock worth $47,894,000 after purchasing an additional 753,208 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in shares of Option Care Health by 15.4% in the first quarter. Westfield Capital Management Co. LP now owns 5,171,385 shares of the company's stock worth $173,448,000 after purchasing an additional 688,653 shares during the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.